New therapies for prostate cancer have emerged over the past three years.
Nevertheless, none of these agents is curative, and unfortunately, patients often ultimately develop resistance to these agents. Therefore, the development of innovative and effective therapies that overcome these resistances is necessary. Unfortunately, the results of a phase III trial evaluating docetaxel in combination with targeted therapies demonstrated no difference in survival. Moreover, scarce data on the combination of a targeted therapy with new agents are currently available. New trials are investigating these possible combination treatments; the results of these (on-going) clinical studies are awaited.
Petrioli R, Francini E, Fiaschi AI, Laera L, Roviello G. Are you the author?
Medical Oncology Unit, University of Siena, Siena, Italy.
Reference: Cancer Invest. 2015 May 7. Epub ahead of print.